SCYX insider trading
NasdaqCM HealthcareSCYNEXIS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About SCYNEXIS INC
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Company website: www.scynexis.com
SCYX insider activity at a glance
FilingIQ has scored 149 insider transactions for SCYX since Feb 25, 2015. The most recent filing in our index is dated Apr 1, 2026.
Across the full history, 62 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SCYX insider trades is 55.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SCYX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading SCYX
13F funds holding SCYX
Frequently asked
- How many insider trades does FilingIQ track for SCYX?
- FilingIQ tracks 149 Form 4 insider transactions for SCYX (SCYNEXIS INC), covering filings from Feb 25, 2015 onwards. 2 of those were filed in the last 90 days.
- Are SCYX insiders net buyers or net sellers?
- Across the full Form 4 history for SCYX, 62 transactions (42%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SCYX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SCYX in?
- SCYNEXIS INC (SCYX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $32.49M.
Methodology & sources
Every SCYX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.